Biosyent Inc. (RX)

Currency in CAD
17.77
-0.33(-1.82%)
Closed·
Trading near 52-week High
RX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.7718.40
52 wk Range
10.6518.40
Key Statistics
Prev. Close
18.1
Open
18.4
Day's Range
17.77-18.4
52 wk Range
10.65-18.4
Volume
10.73K
Average Volume (3m)
8.06K
1-Year Change
65.1487%
Book Value / Share
4.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.00
Upside
+1.29%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

Biosyent Inc. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.00
(+1.29% Upside)

Biosyent Inc. Earnings Call Summary for Q3/2026

  • Q3 2026 revenue surged 64% YoY to CAD 20.1M, driven by Oral Science acquisition; EPS reached CAD 0.25 with CAD 2.9M net income.
  • Company achieved 65th consecutive profitable quarter; debt from Oral Science deal fully repaid by Oct. 1, 2026.
  • THYCONVI liquid levothyroxine launch planned for Q1 2027; FeraMAX expansion targeted for 2028 with international growth details in 2027.
  • Stock traded at $18.10, near 52-week high of $18.25; P/E ratio of 20.78 reflects market confidence in acquisition-driven growth strategy.
  • Over 90% revenue concentration in Canada presents geographic risk; management monitoring consumer trade-down pressure on premium-priced products.
Last Updated: 18/11/2026, 00:32
Read Full Transcript

Earnings

Latest Release
Nov 17, 2026
EPS / Forecast
0.25 / --
Revenue / Forecast
20.08M / 18.3M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.87
Dividend Yield
1.22%
Industry Median 1.91%
Annualised payout
0.22
Paid quarterly
5-Years Growth
-
Growth Streak

RX Income Statement

Compare RX to Peers and Sector

Metrics to compare
RX
Peers
Sector
Relationship
P/E Ratio
20.7x−1.9x−0.2x
PEG Ratio
1.020.020.00
Price/Book
4.5x0.5x2.6x
Price / LTM Sales
3.7x1.1x2.7x
Upside (Analyst Target)
1.3%110.5%69.6%
Fair Value Upside
Unlock12.2%11.7%Unlock

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
473.42K4.19%8.44M
Other Institutional Investors
1.77M15.62%31.50M
Public Companies & Retail Investors
9.07M80.19%161.70M
Total
11.31M100.00%201.64M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
1069867 Ontario Ltd9.62%1,087,76119,395
Intrepid Equity Finance Ltd.4.42%500,0008,915

People Also Watch

39.06
CVE
-3.20%
43.64
BSX
+1.42%
91.70
AKAM
+8.34%
70.62
PPL
-1.34%
35.81
MTY
+0.20%

FAQ

What Is the Biosyent Inc. (RX) Stock Price Today?

The Biosyent Inc. stock price today is 17.77 CAD.

What Stock Exchange Does Biosyent Inc. Trade On?

Biosyent Inc. is listed and trades on the TSX Venture Exchange.

What Is the Stock Symbol for Biosyent Inc.?

The stock symbol for Biosyent Inc. is "RX."

What Is the Biosyent Inc. Market Cap?

As of today, Biosyent Inc. market cap is 200.96M CAD.

What Is Biosyent Inc.'s Earnings Per Share (TTM)?

The Biosyent Inc. EPS (TTM) is 0.87.

When Is the Next Biosyent Inc. Earnings Date?

Biosyent Inc. will release its next earnings report on Mar 17, 2027.

From a Technical Analysis Perspective, Is RX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Biosyent Inc. Stock Split?

Biosyent Inc. has split 0 times.

What is the current trading status of Biosyent Inc. (RX)?

As of Nov 19, 2026, Biosyent Inc. (RX) is trading at a price of 17.77 CAD, with a previous close of 18.10 CAD. The stock has fluctuated within a day range of 17.77 CAD to 18.40 CAD, while its 52-week range spans from 10.65 CAD to 18.40 CAD.

What Is Biosyent Inc. (RX) Price Target According to Analysts?

The average 12-month price target for Biosyent Inc. is 18.00 CAD, with a high estimate of 18 CAD and a low estimate of 18 CAD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.